

## Humanized Monoclonal Antibody against SARS-CoV-2 Spike Protein-1 Receptor-binding Domain (S1RBD)

Catalog Number: 41A245

**Size:** 10 or 100µg

**Type:** Genetically engineered recombinant monoclonal IgG antibody

### Introduction to the molecule

The SARS-CoV-2 glycosylated spike (S) protein highly exposed on the viral surface is a major determinant for virus binding and invasion into host cells, which is a main target for neutralization antibody. The receptor-binding domain (RBD) in SARS-CoV-2 S protein is responsible for binding to human and bat angiotensin-converting enzyme 2 (ACE2) receptors.

### Production:

The cDNA encoding the highly variable region of the antibody recognizing S1RBD from mammalian cells were identified by phage display library, fused with the Fc fragment of human IgG1, and expressed in Chinese Hamster Ovary (CHO) cells.

### Formulation and storage


Liquid in PBS with 0.02% azide, PH7.4. Store at -80°C. Recommend to aliquot the protein into smaller quantities. Avoid repeated freeze-thaw cycles.

### Application/Usage

ELISA and other applications. Optimal concentration/dilution should be determined by the end user.

### Affinity Assay

The binding between immobilized S1RBD (41A231) and the anti-SARS-CoV-2 S1RBD 41A245.



### Reference

1. Shajahan A, *et al.* (2020) Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. bioRxiv, <https://doi.org/10.1101/2020.04.01.020966>.
2. Walls, A C, *et al.* (2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 181(2), 281-292.e6. <https://doi.org/10.1016/j.cell.2020.02.058>.

Website: [www.torontobioscience.com](http://www.torontobioscience.com)

**Brett Wang (Covid-19 Business Development Manager)**

[brett.wang@torontobioscience.com](mailto:brett.wang@torontobioscience.com) or [sales@torontobioscience.com](mailto:sales@torontobioscience.com)

Tel: (+1) 416 417 8573